- Home
- SKE vs ADPT Comparison
SKE vs ADPT Comparison
Compare SKE & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKE
- ADPT
- Stock Information
- Founded
- SKE 1979
- ADPT 2009
- Country
- SKE Canada
- ADPT United States
- Employees
- SKE N/A
- ADPT N/A
- Industry
- SKE Precious Metals
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKE Basic Materials
- ADPT Health Care
- Exchange
- SKE Nasdaq
- ADPT Nasdaq
- Market Cap
- SKE 1.8B
- ADPT 1.8B
- IPO Year
- SKE N/A
- ADPT 2019
- Fundamental
- Price
- SKE $15.65
- ADPT $12.92
- Analyst Decision
- SKE
- ADPT Strong Buy
- Analyst Count
- SKE 0
- ADPT 8
- Target Price
- SKE N/A
- ADPT $12.38
- AVG Volume (30 Days)
- SKE 475.1K
- ADPT 2.1M
- Earning Date
- SKE 08-26-2025
- ADPT 08-05-2025
- Dividend Yield
- SKE N/A
- ADPT N/A
- EPS Growth
- SKE N/A
- ADPT N/A
- EPS
- SKE N/A
- ADPT N/A
- Revenue
- SKE N/A
- ADPT $205,216,000.00
- Revenue This Year
- SKE N/A
- ADPT $24.39
- Revenue Next Year
- SKE N/A
- ADPT $20.44
- P/E Ratio
- SKE N/A
- ADPT N/A
- Revenue Growth
- SKE N/A
- ADPT 21.60
- 52 Week Low
- SKE $7.17
- ADPT $3.98
- 52 Week High
- SKE $17.25
- ADPT $13.37
- Technical
- Relative Strength Index (RSI)
- SKE 53.06
- ADPT 69.79
- Support Level
- SKE $14.74
- ADPT $10.66
- Resistance Level
- SKE $16.33
- ADPT $13.37
- Average True Range (ATR)
- SKE 0.61
- ADPT 0.81
- MACD
- SKE 0.04
- ADPT 0.23
- Stochastic Oscillator
- SKE 73.02
- ADPT 86.82
About SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).